2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Animal Model
PAPER

5037 Preclinical efficacy of dual BCL-2 and aurora kinase a inhibition for TCF3::hlf acute lymphoblastic leukemia

Tommaso Balestra, PhD, Shubhmita Bhatnagar, PhD2, Asen Bagashev, PhD3, Cate Falkenstein, BS4, Jonathan D. Paolino, MD5, Yana Pikman, MD6, Joseph Loftus7, Robert K Chen8, Gerald B Wertheim, MD, PhD9, Christian Hurtz, PhD10, Sarah Tasian, MD11
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
10 Loma Linda University School of Medicine, Loma Linda, California, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, United States, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, United States
Background: TCF3::HLF fusion from t(17;19) comprises a rare (<1%) subtype of B-acute lymphoblastic leukemia (ALL) with frequent KRAS co-mutations. TCF3::HLF ALL remains near-universally fatal despite maximally-intensive chemotherapy and proactive use of hematopoietic stem cell transplantation in patients. While new precision medicine approaches are changing the treatment paradigm for some children with high-risk B-ALL subtypes, including TCF3::HLF (Zeckanovic Haematologica 2025), patients remain at risk of disease recurrence, including antigen loss relapse, following antibody-based or cellular immunotherapies. Recent preclinical studies have also highlighted the therapeutic potential of the BCL2 inhibitor venetoclax for TCF3::HLF ALL, although some cases are only partially sensitive or insensitive. In the present studies, we hypothesized that additional oncogenic vulnerabilities exist in TCF3::HLF that may be successfully co-targeted by clinically available inhibitors that may further synergize with venetoclax.
 
Methods: We conducted a series of in vitro and in vivo experiments using the human HAL-01 cell line and pediatric TCF3::HLF ALL patient derived xenograft (PDX) models (n=6) newly established in immunocompromised NSG mice.  We performed a 49-compound small molecule inhibitor screening assay to identify specific drug sensitivities. In vitro effects of the most promising inhibitors upon TCF3::HLF ALL cell viability, apoptosis, and cell cycle progression were then evaluated via luminescent assays and flow cytometry. Apoptotic dependencies were further characterized using baseline and dynamic BH3 profiling. Immunoprecipitation and Western blotting were performed to assess protein interactions. Comprehensive in vivo inhibitor treatment studies were conducted in PDX models with longitudinal quantitative bioluminescent imaging and/or flow cytometry analysis of human leukemia cells in murine peripheral blood and end-study spleens as described (Hurtz JCI 2020, Pikman Blood Cancer Discovery 2021, Balestra Leukemia 2025).
 
Results: The targeted RasGAP/ERK/RSK inhibitor pluripotin was identified as a lead candidate in our drug screen, inducing robust cytotoxicity of HAL-01 cells. We subsequently validated in vitro anti-leukemia activity of pluripotin and the related clinically-available Aurora kinase A (AURKA) inhibitor (i) alisertib against additional TCF3::HLF KRAS-mutant ALL cells from an immortalized PDX model (ALL1807), but minimal activity of MEKi trametinib and selumetinib. We similarly observed additive enhancement of cell death with co-administration of venetoclax and alisertib or pluripotin, but not with trametinib or selumetinib. BH3 profiling of control and drug-treated TCF3::HLF ALL cells showed high cytochrome c release in the presence of venetoclax or BCL-2i BAD, but not in the presence of other pro-apoptotic peptides, suggesting baseline apoptotic functional dependence primarily upon BCL-2. Co-treatment with alisertib and venetoclax or in presence of apoptotic activator BIM resulted in enhanced apoptotic priming compared to monotherapies, indicating that TCF3::HLF ALL relies on abnormal apoptotic regulation. Using immunoprecipitation assays, we observed that the AURKA/RasGAP interaction in HAL-01 and ALL1807 cells  was abolished following treatment with alisertib, but not with venetoclax. Single-agent alisertib or in combination with venetoclax further induced accumulation of the short pro-apoptotic RasGAP N terminus peptide (N2 fragment), further supporting our hypothesis that alisertib strengthens the anti-leukemia activity of venetoclax via disruption of AURKA/RasGAP interaction. Finally, we observed significantly superior efficacy of alisertib and venetoclax co-therapy in TCF3::HLF ALL PDX models (n=3) compared to AURKAi or BCL2i monotherapies, including long-term ‘cure’ of mice with no evidence of disease detected after >=6 months of treatment in survival analyses.
 
Discussion: Prior studies reported suboptimal anti-leukemia activity of alisertib and dasatinib co-treatment in preclinical TCF3::HLF ALL models (Leonard Haematologica 2021). Our current studies conversely demonstrate potent in vitro and especially in vivo efficacy of dual AURKA and BCL-2 inhibition. We thus posit that co-administration of clinically-available alisertib and venetoclax may have unique therapeutic synergy for children and adolescents/young adults with this deadly leukemia subtype and merit potential clinical investigation.
Tommaso Balestra, PhD: No relevant conflicts of interest to declare.